徐潔傑，博士，復旦大學基礎醫學院教授。2002年獲四川大學華西醫學中心（原華西醫科大學）醫學學士學位，2005年獲四川大學生命科學學院理學碩士學位，2010年獲復旦大學上海醫學院醫學博士學位，之後在復旦大學基礎醫學院做生物學博士後研究，2012年博士後出站留校任教。
基本介紹
人物經歷,教育經歷,工作經歷,研究方向,主要成就,研究成果,主講課程,學術成果,獲獎記錄,社會任職,
人物經歷
教育經歷
1997.09—2002.07 四川大學法醫學專業本科生
2002.09—2005.07 四川大學細胞生物學專業碩士生
2007.09—2010.07 復旦大學病原生物學專業博士生
工作經歷
2010.08—2012.8 復旦大學上海醫學院博士後
2012.09— 復旦大學基礎醫學院教授
研究方向
腫瘤免疫調控的細胞與分子機制
主要成就
研究成果
近年來圍繞腫瘤免疫方向，深入研究腫瘤免疫調控的細胞與分子機制。以第一作者和通訊作者在Gastroenterology、Gut、Hepatology、European Urology、Annals of Oncology、Nature Communications、JAMA Surgery、Annals of Surgery、Clinical Cancer Research、Cancer Research、Cell Death & Differentiation、Journal of Biological Chemistry、European Journal of Cancer、British Journal of Cancer、International Journal of Cancer、Oncoimmunology、Cancer Immunology Immonotherapy、Cell Death & Disease、Glycobiology等腫瘤學領域國際權威期刊發表SCI論文35篇，其中第一作者論文3篇，通訊作者論文32篇，ESI高被引論文1篇，影響因子10以上論文7篇，最高影響因子為19.233。
發現腫瘤細胞抑癌基因Notch1失活以及癌基因PAK1、CXCR4激活等腫瘤細胞促癌信號活化通過影響腫瘤細胞衰老樣生長抑制和失巢凋亡等生物學行為促進肝癌發生髮展的分子機制，闡明腫瘤相關巨噬細胞等腫瘤浸潤免疫細胞功能表型變化在腫瘤細胞促癌信號誘導免疫逃逸形成過程中的關鍵作用及其細胞分子機制，這些發現對於認識腫瘤免疫逃逸形成機制具有重要意義，同時也為腫瘤免疫治療提供了新的靶點。
多次受邀為Lancet、Lancet Oncology、Hepatology、Journal of the American Society of Nephrology、International Journal of Cancer、Molecular Cancer、Cancer Letters、Endocrine-Related Cancer、Cancer Immunology Immonotherapy、Journal of Hematology & Oncology、Cell Death & Disease等國際知名腫瘤學期刊審稿。
主講課程
課題來源 課題編號
國家自然科學基金 31770851 （面上項目）
國家自然科學基金 81472227 （面上項目）
國家自然科學基金 31270863 （面上項目）
國家科技部 2012ZX10002-012-007 （國家科技重大專項子課題）
上海市科委 13QA1400300 （上海市青年科技啟明星計畫）
教育部 NCET-13-0146 （教育部新世紀優秀人才支持計畫）
復旦大學 EZF101354 （復旦大學卓學計畫）
學術成果
代表性論文列表 (* 為通訊作者)
1. Zeng H, Liu Z, Wang Z, Zhou Q, Qi Y, Chen Y, Chen L, Zhang P, Wang J, Chang Y, Bai Q, Xia Y, Wang Y, Liu L, Zhu Y, Dai B, Guo J, Xu L*, Zhang W*,Xu J*.Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.Int J Cancer. 2020;146(2):542-552.(共同通訊作者，IF=4.982)
2. Lin C, He H, Liu H, Li R, Chen Y, Qi Y, Jiang Q, Chen L, Zhang P, Zhang H, Li H, Zhang W*, Sun Y*,XuJ*.Tumor-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer.Gut. 2019;68(10):1764-1773.(共同通訊作者，IF=17.943)
3. Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Qi Y, Hu B, Fu H, Xie H, Zhou L, Chang Y, Zhu Y, Dai B*, Zhang W*,Xu J*.Tumor-associated macrophage-derived IL-23 interlinks kidney cancer glutamine addiction with immune evasion.Eur Urol. 2019;75(5): 752-763.(共同通訊作者，IF=17.298)
4. WangJT, Li H, Zhang H, Chen YF, Cao YF, Li RC, Lin C, Wei YC, Xiang XN, Fang HJ, Zhang HY, Gu Y, Liu X, Zhou RJ, Liu H, He HY, Zhang WJ*, Shen ZB*, Qin J*,Xu JJ*.Intratumoral IL17-producing cells infiltration correlate with anti-tumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer.Ann Oncol. 2019;30(2): 266-273.(共同通訊作者，IF=14.196)
5. Wang J, Liu L, Bai Q, Ou C, Xiong Y, Qu Y, Wang Z, Xia Y, Guo J*,XuJ*.Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma.Oncoimmunology. 2019; 8(1): e1515611.(共同通訊作者，IF=5.333)
6. Qi Y, Chang Y, Wang Z, Chen L, Kong Y, Zhang P, Liu Z, Zhou Q, Chen Y, Wang J, Bai Q, Xia Y, Liu L, Zhu Y, Xu L, Dai B, Guo J, Wang Y*,Xu J*,Zhang W*.Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.Cancer Immunol Immunother. 2019;68(12):2067-2080.(共同通訊作者，IF=4.900)
7. Xiong Y, Liu L, Xia Y, Qi Y, Chen Y, Chen L, Zhang P, Kong Y, Qu Y, Wang Z, Lin Z, Chen X, Xiang Z, Wang J, Bai Q, Zhang W, Yang Y, Guo J*,Xu J*.Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma.Cancer Immunol Immunother. 2019;68(5):731-741.(共同通訊作者，IF=4.900)
8. Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L, Zhu Y, Wang Y, Zhang W*,Xu J*.CD19(+) tumor-infiltrating B-cells prime CD4(+) T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer.Cancer Immunol Immunother. 2019;68(1): 45-56.(共同通訊作者，IF=4.900)
9. Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D*,Xu J*.Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer.Clin Cancer Res. 2018; 24(13): 3069–78.(共同通訊作者，IF=8.911)
10. Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X,Xu J*,Sun Y*. Tumor infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer.Ann Surg. 2018; 267(2): 311-318.(共同通訊作者，IF=9.476，ESI高被引論文)
11. Lin Z, Liu L, Xia Y, Chen X, Xiong Y, Qu Y, Wang J, Bai Q, Guo J*,XuJ*.Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.Oncoimmunology. 2018; 7(10): e1477461.(共同通訊作者，IF=5.333)
12. Liu Z, Zhu Y, Xu L, Zhang J, Xie H, Fu H, Zhou Q, Chang Y, Dai B*,Xu J*.Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.Oncoimmunology. 2018; 7(9): e1474317.(共同通訊作者，IF=5.333)
13. Wu S, He H, Liu H, Cao Y, Li R, Zhang H, Li H, Shen Z*, Qin J*,Xu J*.C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.Oncoimmunology. 2018; 7(6): e1433517.(共同通訊作者，IF=5.333)
14. Wei Y, Lin C, Li H, Xu Z, Wang J, Li R, Liu H, Zhang H, He H*,Xu J*. CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer.Cancer Immunol Immunother. 2018; 67(2): 261-269.(共同通訊作者，IF=4.900)
15. Wang J, Liu L, Qu Y, Xi W, Xia Y, Bai Q, Xiong Y, Long Q,Xu J*,Guo J*. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.Cancer Immunol Immunother. 2018; 67(1): 79-87.(共同通訊作者，IF=4.900)
16. Cao Y, Liu H, Li H, Lin C, Li R, Wu S, Zhang H, He H*, Zhang W*,Xu J*.Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.JAMA Surg. 2017; 152(11): e173120.(共同通訊作者，IF=10.668)
17. Liu Y, Liu H, Yang L, Wu Q, Liu W, Fu Q, Zhang W, Zhang H,Xu J*,Gu J*. Loss of N-acetylgalactosaminyltransferase-4 orchestrate oncogenic microRNA-9 in hepatocellular carcinoma.J Biol Chem. 2017; 292(8): 3186-200.(共同通訊作者，IF=4.106)
18. Zhu Y, Liu Z, Wang Y, Fu H, Wang Z, Xie H, Zhang J, Li G, Dai B,Xu J*,Ye D*. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients.Oncoimmunology. 2017; 6(11): e1359450.(共同通訊作者，IF=5.333)
19. Wang J, Lin C, Li H, Li R, Wu Y, Liu H, Zhang H, He H, Zhang W*,Xu J*.Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefits in patients with gastric cancer.Oncoimmunology. 2017; 6(11): e1353858.(共同通訊作者，IF=5.333)
20. Zhou L, Xu L, Chen L, Fu Q, Liu Z, Chang Y, Lin Z*,Xu J*.Tumor infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer.Oncoimmunology. 2017; 6(4): e1293211.(共同通訊作者，IF=5.333)
21. Liu H, Liu Y, Liu W, Zhang W,XuJ*.EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma.Nat Commun. 2015; 6: 8494.(通訊作者，IF= 11.878)
22. Zhang W, Liu H, Liu W, Liu Y,Xu J*.Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF-κB pathway.Cell Death Differ. 2015; 22(2): 287-97.(通訊作者，IF=8.086)
23. Liu W, Liu Y, Liu H, Zhang W, Fu Q,Xu J*,Gu J*. Tumor suppressive function of p21-activated kinase 6 in hepatocellular carcinoma.J Biol Chem. 2015; 290(47): 28489-501.(共同通訊作者，IF=4.106)
24. Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, Yang L, Fu Q,Xu JJ*,Gu JX*. Decreased Expression of Hnf4α/miR-122 Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Activity.J Biol Chem. 2015; 290(2): 1170-85.(共同通訊作者，IF=4.106)
25. An H, Xu L, Chang Y, Zhu Y, Yang Y, Chen L, Lin Z*,XuJ*.CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.Eur J Cancer. 2015; 51(14): 1953-61.(共同通訊作者，IF=6.680)
26. Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L, Zhang W*,XuJ*.Prognostic Value of Interleukin-6 and Interleukin-6 Receptor in Organ-Confined Clear-Cell Renal Cell Carcinoma: A 5-Year Conditional Cancer-Specific Survival Analysis.Br J Cancer. 2015; 113(11): 1581-1589.(共同通訊作者，IF=5.416)
27. Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z*,XuJ*.Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma.Br J Cancer. 2015; 113(4): 626-33.(共同通訊作者，IF=5.416)
28. Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y, Lin Z,Xu J*.p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.Cell Death Dis. 2015; 6: e1637.(通訊作者，IF=5.959)
29. Zhang H, Wang X,XuJ*,Sun Y*. Notch1 activation is a poor prognostic factor in patients with gastric cancer.Br J Cancer. 2014; 110(9): 2283-90.(共同通訊作者，IF=5.416)
30. An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu H, Chen L*,Xu J*,Lin Z*. High C-X-C chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma.Br J Cancer. 2014; 110(9): 2261-8.(共同通訊作者，IF=5.416)
31. He H, Shen Z, Zhang H, Wang X, Tang Z,Xu J*,Sun Y*. Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.Br J Cancer. 2014; 110(8): 2021-9.(共同通訊作者，IF=5.416)
32. Liu J, Liu H, Zhang W, Wu Q, Liu W, Liu Y, Pan D,Xu J*,Gu J. N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation.Glycobiology. 2013; 23(9): 1097-109.(通訊作者，IF=4.194)
33.Xu J,Liu H (co-first author), Chen L, Wang S, Zhou L, Yun X, Sun L, Wen Y*, Gu J*. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1.Gastroenterology. 2012; 143(1): 199-212.e4.(並列第一作者，IF=19.233)
34. Liu H,Xu J (co-first author),Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y*, Gu J*. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway.Cancer Res. 2011; 71(24): 7547-57.(並列第一作者，IF=8.378)
35.Xu J,Yun X, Jiang J, Wei Y, Wu Y, Zhang W, Liu Y, Wang W, Wen Y*, Gu J*. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage.Hepatology. 2010; 52(1): 142-54.(第一作者，IF=14.971)
獲獎記錄
2020，國家級青年人才
2013，教育部新世紀優秀人才，教育部
2013，上海市青年科技啟明星，上海市科委
社會任職
British Journal of Cancer雜誌編委會委員
癌症免疫治療協會（Society for Immunotherapy of Cancer, SITC）會員
美國癌症研究聯合會（American Association of Cancer Research, AACR）會員
